Remove

Pages Columns Lines

Passages or Relevant

where Relevant

Figures Appear

	Application Number		10001245	
	Filing Date		2001-11-15	
	First Named Inventor Jer		Jens Holm	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1644	
NOTION SUBMISSION UNDER ST OF R 1.337	Examiner Name Nora		a Maureen Rooney	
	Attorney Docket Numb	er	27554-0007001	

U.S. PATENTS

				0.5.	TAILINIS	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7029686	B2	2006-04-18	Sturaro et al.	
	2	7485708	B2	2009-02-03	Burks et al.	
If you wish	h to add	additional U.S. Pater	nt citatio	n information p	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020064530	A1	2002-05-30	Sturaro et al.	
	2	20030049237	A1	2003-03-13	Bannon et al.	
If you wish	h to add	additional U.S. Public	shed Ap	plication citatio	n information please click the Ad-	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

Kind Publication

Code⁴ Date

A2 2000-09-08 Name of Patentee or

Applicant of cited

Document

Rannon et al

Examiner Cite

Initial*

Foreign Document

WO2000052154

Number³

Country

Code2 i

wo

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10001245	
Filing Date		2001-11-15	
First Named Inventor	Jens	Holm	
Art Unit		1644	
Examiner Name Nora		Maureen Rooney	
Attorney Docket Number		27554-0007001	

	2	WO2002022674	wo	A2	2002-03-21	Sturaro et al.		
	3	WO2002022679	wo	A2	2002-03-21	Sturaro et al.	also published as US2002064530 and US7029686	
	4	WO1999038978	wo	A1	1999-08-05	Bannon et al.	also published as US2003049237 and US7485708	
If you wisl	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. (by and/or country where publisher)						Ţ5
	1	Patentee's grounds of appeal, filed March 14, 2012, during opposition proceedings to EP1373510 (18 pages).						
	2	Patenties's submission in preparation of oral proceedings, filed July 20, 2011, during opposition proceedings to EP1373510 (73 pages).						
	3	Minutes of crait proceedings held in connection with apposition proceedings to EP1373510, dated November 4, 2011 (13 pages).						
	4	Interlocutory decision issued in connection with opposition proceedings to EP1373518, dated November 4, 2011 (31 pages).						
	5	5 Opponents submission dated March 7, 2012, filed during opposition to EP1373510 (62 pages)						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10001245		
Filing Date		2001-11-15		
First Named Inventor	Jens Holm			
Art Unit		1644		
Examiner Name Nora		Maureen Rooney		
Attorney Docket Number		27554-0007001		

7	Wikipedia entry for Protein Dala Bank, printed September 17, 2011 (6 pages).	
8	Wikipedia entry for Accessible surface area, printed September 16, 2011 (4 pages).	
9	Opponent's submission dated March 5, 2012, filed during opposition proceedings to EP1062341, with selected attachments (80 pages).	
10	KING, Thesis entitled, "Modulation of the Allergenicity of a Major Peanut Allergen Are in 2 By Site-Directed Mutageness of its IgE Binding Epitopes" (1999) (136 pages).	
11	ASTURIAS et al., "Par j 1 and Par j 2, the major allergens from Parietana judaica pollen, have similar immunoglobulin E epitopes", Clin. Exp. Allergy (2003); 33.518-524.	
12	BREITENEDER et al., Tour recombinant automns of Cor a I, the major allergen of hazel pollen, show different (ge- binding properties*, Eur. J. Brochem. 212, 355-362 (1993).	
13	BURKS et al., "Mapping and mulational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity", Eur. J. Biochem, 245, 334-339 (1997).	
14	GAJ, "Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis", Allergy (1998), 53:165-172.	
15	HOLM et al., "Allergy Vaccine Engineering: Epitope Modulation of Recombinant Bet v 1 Reduces IgE Binding but Retains Protein Foding Pattern for Induction of Protective Biocking-Antibody Responses", The Journal of Immunology, pp5238-5267 (2004)	
16	JONES, "Learning Chemistry though Design and Construction", Published in UnServe Science News, 14, November, 3-7, 1999 (7 pages).	
17	LASKOWSN, "SURFNET: A program for visualizing molecular surfaces, cavilies, and intermolecular interactions", Journal of Molecular Graphics 13:323-330 (1995).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examin

Application Number		10001245		
Filing Date		2001-11-15		
First Named Inventor	Jens	Holm		
Art Unit		1644		
Examiner Name	Nora Maureen Rooney			
Attorney Docket Number		27554-0007001		

	18	NCBI, "The Statistics of Sequence Smillarity Scores", downloaded from http://www.ncbi.n/m.n/h.gov/BLAST/hutonal/ Altschul-1.html September 16, 2011 (13 pages).						
	19	BERNSTEIN, "The Historical Context of RasMol Development", (2000) downloaded http://www.OpenRasMol.org/ history.html (5 pages).						
	20	RCSB PDB, "About the PDB Archive and the RCSB PDB, downloaded from http://lwww.rcsb.org/pdb/stalic.do? prigeneral_information%2Fabout_pdb%2Findex.html, Cotober 19, 2011 (1 page).						
	21	Fracticevicz and Braun, "Calculation of Solvent Accessible Surface Areas, Alornic Solvation Energies and Their Grandients for Macromolecules", The University of Texas Medical Branch, downloaded from http://curie.utmb.edu/ getarea.html on October 14, 2011 (1 page).						
	22	Rodriguez et al., "Homology modeling, model and software evaluation: three related resources", downloaded from http://www.nobi.nim.nsh.gov/pubmed/9694901 on October 20, 2011 (1 page).						
If you wish to add additional non-patent literature document citation information please click the Add button Add								

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Examine organizer Data Considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 See Kind Codes of USPT/D Pattern Documents at year LISPT/D,COQ/or VMEPP 901.64. ² Either office that issued the document, by the ho-effect code (WIPP D Standard ST.3). ² For dupratere plants froutments, by the advanced by the order may be recommended to the comment. The major of the Emprover must precede the serial number of the pattern document. ² Kind of document by the appropriate symbols as indicated on the document under WIPP Standard ST.16 if possible. ³ Applicant is to place a check mark here it English tanguage the resistation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10001245	
Filing Date		2001-11-15	
First Named Inventor	Jens Holm		
Art Unit		1644	
Examiner Name	Nora Maureen Rooney		
Attorney Docket Number		27554-0007001	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 t	o make the	appropriate selection(s):
---------------	----------	------------	------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.	of the signature.							
Signature	/Mrtchell Bernstein, Reg. No. 46,550/	Date (YYYY-MM-DD)	2012-07-07					
Name/Print	Mitchell Remstein	Registration Number	46550					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. DING YESP IEEE SING COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
 request involving an individual, to whom the record pertains, when the individual has requested assistance from the
 Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, a samended, ourspan to 5 U.S.C. S524mi).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a noutine use, to the Administrator, General Services, or hisher designes, during an inspection of records conducted by GSAs a part of that agency? responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other intervant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abant individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.